title: Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer.
abstract: The clinical use of 5-fluorouracil, one of the drugs of choice in colon cancer therapy, is limited by a nonuniform oral absorption, a short plasma half-life, and by the development of drug resistances by malignant cells. We hypothesized that the formulation of biodegradable nanocarriers for the efficient delivery of this antitumor drug may improve its therapeutic effect against advanced or recurrent colon cancer. Hence, we have engineered two 5-fluorouracil-loaded nanoparticulate systems based on the biodegradable polymers poly(butylcyanoacrylate) and poly(ε-caprolactone). Drug incorporation to the nanosystems was accomplished by entrapment (encapsulation/dispersion) within the polymeric network during nanoparticle synthesis, i.e., by anionic polymerization of the monomer and interfacial polymer disposition, respectively. Main factors determining 5-fluorouracil incorporation within the polymeric nanomatrices were investigated. These nanocarriers were characterized by high drug entrapment efficiencies and sustained drug-release profiles. In vitro studies using human and murine colon cancer cell lines demonstrated that both types of nanocarriers significantly increased the antiproliferative effect of the encapsulated drug. In addition, both nanoformulations produced in vivo an intense tumor growth inhibition and increased the mice survival rate, being the greater tumor volume reduction obtained when using the poly(ε-caprolactone)-based formulation. These results suggest that these nanocarriers may improve the antitumor activity of 5-fluorouracil and could be used against advanced or recurrent colon cancer.
authors.affiliation: Department of Health Science, University of Jaén, 23071, Jaén, Spain.
authors.forename: Raúl
authors.initials: R
authors.lastname: Ortiz
authors.forename: Laura
authors.initials: L
authors.lastname: Cabeza
authors.forename: José L
authors.initials: JL
authors.lastname: Arias
authors.forename: Consolación
authors.initials: C
authors.lastname: Melguizo
authors.forename: Pablo J
authors.initials: PJ
authors.lastname: Álvarez
authors.forename: Celia
authors.initials: C
authors.lastname: Vélez
authors.forename: Beatriz
authors.initials: B
authors.lastname: Clares
authors.forename: Antonia
authors.initials: A
authors.lastname: Áranega
authors.forename: Jose
authors.initials: J
authors.lastname: Prados
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003487:Cyanoacrylates / Q000737:chemistry; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D004659:Enbucrilate; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D011091:Polyesters / Q000737:chemistry
chemical_list: D000964:Antimetabolites, Antineoplastic; D003487:Cyanoacrylates; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011091:Polyesters; C016240:polycaprolactone; D004659:Enbucrilate; D005472:Fluorouracil